MicroRNA-503 promotes angiotensin II-induced cardiac fibrosis by targeting Apelin-13

Yuhong Zhou a, Lin Deng a, Dandan Zhao a, Lanlan Chen a, Zhen Yao a, Xiaowei Guo a, Xue Liu a, Lifang Lv a, Bing Leng a, Wei Xu b, Guofen Qiao a, Hongli Shan a, *

a Department of Pharmacology (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), Harbin Medical University, Harbin, China
b Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, China

Received: July 1, 2015; Accepted: November 4, 2015

Abstract

Cardiac fibrosis is a major cause of heart failure. MicroRNAs (miRs) are important epigenetic regulators of cardiac function and cardiovascular diseases, including cardiac fibrosis. This study aimed to explore the role of miR-503 and its mechanisms in regulating cardiac fibrosis. miR-503 was found up-regulated in the mouse LV tissues subjected to transverse aortic constriction (TAC) and in neonatal cardiac fibroblasts (CFs) cultured with Angiotension II. The role of miR-503 in regulating CF cell proliferation and/or collagen production in mice neonatal CFs were determined using an MTT assay and RT-PCR respectively. Forced expression of miR-503 increased the cellular proliferation and collagen production in mice neonatal CFs. The effects were abrogated by cotransfection with AMO-503 (a specific inhibitor of miR-503). Injection of antagomiR-503 elevated cardiac function and inhibited the expression of connective tissue growth factor (CTGF) and transforming growth factor (TGF)-β in the TAC mice. Additional analysis revealed that Apelin-13 is a direct target of miR-503, as the overexpression of miR-503 decreased the protein and mRNA expression levels of Apelin-13. In the CFs with pre-treatment of AngII, we transfected AMO-503 into the cells treated with siRNA-APLN. siRNA-APLN abolished the effects of AMO-503 on the production of collagen I and III and the expression of TGF-β and CTGF. Furthermore, pre-treatment of CFs with Apelin-13 (1–100 nmol/l) inhibited angiotensin II-mediated collagen production and activation of CTGF and TGF-β. So we conclude that miR-503 promotes cardiac fibrosis via miR-503-Apelin-13-TGF-β-CTGF-collagen production pathway. Thus, miR-503 is a promising therapeutic target for reducing cardiac fibrosis.

Keywords: Apelin-13 ● miR-503 ● cardiac fibrosis

Introduction

Cardiac fibrosis is mainly induced by various cardiac injuries, such as myocardial infarction, chronical hypertension and so on. During the process, normal cardiac resident fibroblasts (CFs) and/or circulating fibroblasts become myofibroblast cells. These myofibroblasts produce and secrete excess amounts of extracellular matrix (ECM) commonly including collagen I, collagen III and fibronectins, etc. [1]. Cardiac fibrosis can alter many structural and functional aspects of the heart, which accompanies with myocardial remodelling and leads to eventual heart failure [2, 3]. Therefore, great efforts have been made to better understand this pathological process and to uncover its underlying molecular mechanisms.

MicroRNAs (miRNAs) are a class of small non-coding RNAs binding to the complementary sequences in the 3’-untranslated regions of target mRNAs of protein-coding genes to repress protein expression at the post-transcription level. More and more evidences have been shown that miRNAs have critical roles in participating and regulating various cardiovascular diseases, such as cardiac arrhythmia [4], cardiac hypertrophy [5, 6], cardiac injuries [7] and finally the heart failure [8]. It has been reported that several miRNAs are involved in the development and progression of cardiac fibrosis. miR-21 and miR-29 provoke the development of fibrosis, while miR-133 and miR-101 [9–12] suppress the fibrotic responses of CFs via the regulation of various fibrosis-related proteins. Many miRNAs have been found involved specifically in cardiac fibrosis. As Dr. Dai mentioned that an improved understanding of the role of multiple miRs targeting several different signalling pathways will provide novel and exciting therapeutic modalities [13].

Apelin is a secreted peptide belonging to the adipokine family. It regulates cardiovascular functions via its binding to the APJ receptor [14]. Apelin has many various fragments and Apelin-13 is the main...
one. It has been reported that Apelin-13 plays a central role in CF activation. Apelin-13 inhibits transforming growth factor (TGF-β)-induced phenotypic switching of fibroblast-to-myofibroblast via a SphK1-dependent mechanism [15]. Apelin-13 increases angiogenesis and attenuates cardiac fibrosis and hypertrophy, and also improves cardiac repair post-MI by up-regulating SDF-1α/CXCR-4 in vascular progenitor cells [16]. However, little is known about the regulatory factors that modulate Apelin-13, or the mechanisms underlying this process. To study potential epigenetic regulation of Apelin-13 protein level, we performed Target Scan and found miR-503 is a match candidate.

miR-503 was first identified in human retinoblastoma tissues [17]. Considering the seed sequence similarities and the genomic organization, it is possible to classify miR-503 as part of the extended miR-16 family [18]. Members of this family are miR-15a/b, miR-16, miR-195, miR-424 and miR-497. The expression of miR-503 was found to be increased in human parathyroid carcinomas and adenocortical carcinomas [19, 20]. It is critical for the differentiation of myoblasts and myogenesis. In vivo, miR-503 is up-regulated in myocardial ECs from diabetic GK rats and in ECs resident in ischaemic limb muscles of diabetic mice [21, 22]. It is also up-regulated in ischaemic limb skeletal muscles and the plasma of diabetic patients with end-stage critical limb ischaemia [21]. It was believed that miR-503 was involved in the regulating cellular differentiation and modulating the cell cycle.

Based on the information provided by Target Scan, we suggested that miR-503 was a major miR that controls the expression of Apelin-13 in CFs. To explore this hypothesis by transfaction and real-time quantitative RT-PCR analysis, we tested whether miR-503 can alter the expression level of Apelin-13 in neonatal CFs. With a series of biochemical analyses, we demonstrated that miR-503 acts directly on Apelin-13 mRNA and this miR-503-dependent down-regulation of Apelin-13 can lead to the repression of the TGF-β-connective tissue growth factor (CTGF) pathway, which ultimately induced excessive ECM deposition and cardiac fibrosis. This study implies that manipulating the expression level of miR-503 represents a promising therapeutic strategy potentially for the treatment of cardiac fibrosis.

**Materials and methods**

**Ethics statement**

All animal experiments were approved by the Committee on Animal Experimentation of Harbin Medical University (Approval ID: DEC6121) and were conducted in accordance with international guidelines regarding animal experimentation.

**Animals and housing conditions**

Male C57BL6/J mice aged 8–10 weeks and weighing 20–25 g were obtained from the Animal Centre of Harbin Medical University. During the experiment, the animals were kept on a 12 hr light: 12 hr dark cycle and were granted ad libitum access to food and water.

**Surgical procedures of TAC**

To induce pressure-overload heart hypertrophy, animals were subjected to transverse aortic constriction (TAC). Adult Male C57BL6/J mice were anaesthetized with pentobarbital (65 mg/kg, intraperitoneal injection). Animals were placed in the supine position. After successful endotracheal intubation, the cannula was connected to a volume-cycled rodent ventilator (UGO BASILE S.R.L. Italy). The chest was opened and the thoracic aorta was identified. A 7–0 silk suture was placed around the transverse aorta and tied around a 26-gauge blunt needle which was subsequently removed. The chest was closed and the animals were kept ventilated until recovery of autonomic breath. All surgical procedures were performed under sterile conditions. The cholesterol-conjugated miR-503 antisense and negative control (antagomiR-503 and antagomiR-NC, respectively) were purchased from RiboBio (Guangzhou, China). After TAC surgery, we injected antagomiR-503 (30 mg/kg bw in 50 μl) and antagomiR-NC (30 mg/kg bw in 50 μl) one time a day by tail vein on days 1, 2, 8, 9, 15 and 16. After 28 days, we evaluate their cardiac function and measure the fibrotic factors using heart tissue. The heart was quickly excised and frozen in liquid nitrogen and stored at −80°C for subsequent western blot or real-time PCR analysis. All procedures involving animals and their care were approved by the Institutional Animal Care and Use Committee of Harbin Medical University, China.

**Echocardiographic measurements**

Four weeks after the injection of antagomiR-503 and antagomiR-NC, we used transthoracic echocardiography with an ultrasound machine (Vivid 7GE Medical, Horten, Norway) equipped with a 10-MHz phased-array transducer to test the LV function. LV systolic diameter, left ventricular diastolic diameter (LVDd), interventricular septum diastolic thickness (IVSd) and interventricular septum systolic thickness (IVSs) were measured, and left ventricular ejection fraction (EF) and fractional shortening (FS) were calculated from M-mode recording. After functional measurement, mice were killed with overdose sodium phenobarbital. The hearts were collected and put in liquid nitrogen or 4% paraformaldehyde for use.

**Cell culture**

Mice neonatal CFs were isolated and cultured as previously described [11]. Briefly, hearts from 2- to 3-day-old mice were finely minced and digested using type II collagenase (120 units/ml; Worthington Biochemical Corp., Lakewood, NJ, USA) for 10 min. every time, supernatant fluid were collected. Fibroblasts were isolated by removal of myocytes through selective adhesion of non-myocytes at a 1.5 hrs pre-plating interval. Cardiac fibroblasts were maintained in DMEM supplemented with penicillin and streptomycin (1%) and fetal bovine serum (FBS) (10%). Cardiac fibroblasts at the second passage were used in the experiments.

**Transfection**

miR-503 and their antisense oligonucleotides, AMO-503 were synthesized by GenePharma (GenePharma Co. Ltd., Shanghai, China). A
scrambled RNA was used as negative control. Transfections of miR-503 and AMO-503 were performed with Lipofectamine 2000 (Invitrogen, Life Technologies, Carlsbad, CA, USA) according to the procedure specification. The same procedures described elsewhere [12].

Construction of the plasmid expressing small interfering RNA (siRNA) for rat Apelin

The siRNA for Rattus norvegicus APLN was constructed by using plasmid pGCsilencerm® U6/Neo/GFP/RNAi Expression Vector (GeneChem Co. Ltd., Shanghai, China), which contained a human U6 promoter, a GFP reporter gene and a neomycin resistance gene to enable antibiotic selection in mammalian cell. Three target sequences of rattus APLN mRNA were constructed. They were APLN RNAi-: GGCUAGAAGAAGGCAAUTT-AUGUUGCCUCUUCUA GCCTT. These different short-hairpin RNA (shRNA) sequences were inserted into pGCsilencerm® U6/Neo/GFP/RNAi-specific shRNA vector (pGCSi:U6:Neo/GFP RNAi-NC Plasmid) was constructed by insertion of a sequence that expresses a shRNA with no significant homology to APLN mRNA gene and which had the sequence not present in the mouse, human or rat genome databases. The control insert sequence was: 5'-TTCTCCGAACGTGTCACGTTTCAAGAGAACGTGACACGTTCGGAGAA-3'.

Luciferase assays

To construct reporter vectors bearing miRNA-target sites, we first obtained fragments of the 3'UTRs of Apelin (rat and mouse) containing the exact target sites for miR-503 by PCR amplification. Apelin 3'UTRs was inserted into the multiple cloning sites downstream the luciferase gene (HindIII and SacI sites) in the pMIR-REPORT™ luciferase miRNA expression reporter vector (Ambion, Inc., Austin, TX, USA.) to form chimeric plasmid.

After that, 1 μg of the chimeric plasmid (firefly luciferase vector), 0.1 μg PRL-TK (TK-driven Renilla luciferase expression vector) and the appropriate miRNAs or their inhibitors were cotransfected with lipofectamine 2000 (Invitrogen, Life Technologies, Carlsbad, CA, USA) into HEK-293 cells (1 × 105/well). Luciferase activities were measured with a dual luciferase reporter assay kit (Promega, Madison, WI, USA) on a luminometer (GloMax™ 20/20), 48 hrs following transfection. For all experiments, transfection took place 24 hrs after starvation of cells in serum-free medium. The normalized luciferase activity relative to control group was used to demonstrate the alteration of mRNA transcription.

Real-time reverse transcript polymerase chain reaction

After the experimental treatment, total RNA from cultured fibroblasts and cardiac tissues were isolated using Trizol reagent (Invitrogen) [12]. Total RNA (0.5 μg) was then reverse transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) to obtain cDNA. The RNA levels of Apelin-13, TGF-β1, collagen I, collagen III and CTGF were determined using SYBR Green I incorporation method on ABI 7500 fast Real-Time PCR system (Applied Biosystems), with β-actin as an internal control. The forward and reverse PCR oligonucleotide primers are listed in Table 1. The level of miR-503 was tested using TaqMan MicroRNA Assay Kit (Applied Biosystems), with U6 as an internal control.

Western blot analysis

Western blotting was performed as previously described [11]. Briefly, cells were lysed with modified RIPA buffer for 30 min. on ice, and cell lysates were subsequently centrifuged at 12,000 × g for 20 min. at 4°C. The supernatant was transferred to a fresh ice-cold tube, and protein concentrations were determined via a Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). Equal concentrations of proteins were mixed with SDS sample

Table 1 Primers Designed With Mice-specific Genes for RT-PCR

| Name       | Accession no. | Primer Sequence                      |
|------------|---------------|-------------------------------------|
| Collagen I | HB1211290011  | F: AAGAAGACATCCCTGAAGTCA            |
|            |               | R: TTGTGCAGATACAGATCAAG             |
| Collagen III | HB1211290011 | F: TTGGGATGCGCCACCTTGG             |
|            |               | R: CGCAAAAGACAGATCTCTGAG            |
| Apelin-13  | HB1210100052  | F: GGCTAGAAGAAGGCAACATGC           |
|            |               | R: CCGCTGTCTGCGAAAAATTTTCT         |
| APJ        | HB1210100052  | F: CCACCTGGTGAAAGACTCTCTACA        |
|            |               | R: CTGACGTAACGTGAGCGGAGTG          |
| CTGF       | HG1403181051  | F: AACTTCCACCCCGAGTTACCA           |
|            |               | R: AACCTAGCCCTGATATGCTCTCAC        |
| TGF-β1     | HG1403181051  | F: GACTTCCACCTGCAAGACC            |
|            |               | R: CCGCTGTCTGCGAAAAATTTTCT         |
| miR-503    | HB1209260003  | RT: GTCGTATCCAGTGCGTGTCGAGTCAAGG   |
|            |               | F: GCCTAGAAGGCGGAAAGT             |
|            |               | R: CCAGAGCGGCGGAGAGTT             |

© 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
buffer and denatured at 95°C for 5 min. Samples were resolved with 8% SDS-page gel for protein. Gels were then transferred onto nitrocellulose membrane paper, and the membranes were blocked with 5% non-fat dried milk in TTBS (0.1% Tween-20) for 1 hr. Following blocking, the blots were incubated overnight with primary antibodies at 4°C. The anti-Apelin-13, anti-CTGF and anti-TGF-β antibodies were obtained from Santa Cruz Biotech (Santa Cruz, CA, USA). Following washing with TTBS, the membranes were incubated with HRP-conjugated secondary antibodies (1:5000; Santa Cruz Biotechnology) for 1 hr. Finally, the membranes were washed again with TTBS, and the blots were determined using an enhanced chemiluminescence detection system (ECL; GE Healthcare, Bio-Science AB, Uppsala, Sweden).

**CFs proliferation assay**

Both cell counting and a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell vitality assay were used to measure CFs proliferation. CFs were seeded onto 96-well tissue culture plates (5 × 10^3 cells per well) in DMEM with 10% FBS. Following culturing in serum-free Dulbecco-modified Eagle medium for 24 hrs, Angiotensin II (AngII, 100 nmol/l; Sigma-Aldrich, St. Louis, MO, USA), either alone or in combination with miR-503 (50 nmol/l), miR-503-AMO-503 (100 nmol/l, the specific inhibitor of miR-503). Following 48 hrs of incubation, CFs were trypsinized and counted with a haemocytometer. The CFs was then treated with MTT (5 mg/ml) for 4 hrs at 37°C. The amount of metabolized MTT was determined using a microplate reader.

**Statistical analysis**

All values are expressed as the means ± S.E.M. Differences between the two groups were determined via a Student’s t-test. Comparisons between more than two groups, data were assessed using one-way ANOVA, followed by a Bonferroni correction. A value of $P < 0.05$ was considered statistically significant.

**Results**

**Up-regulation of miR-503 in TAC hearts, Ang II and serum-treated mice CFs**

The expression of miR-503 was first detected in TAC cardiac ventricles and cultured CFs treated with serum and AngII. Twenty-eight days following TAC, the expression of miR-503 in cardiac ventricles was increased compared with sham-operated animals (Fig. 1A). miR-503 expression was higher in cultured in the serum containing medium compared to no serum condition (Fig. 1B). Treatment with 100 nmol/l of AngII also increased the expression of miR-503 (Fig. 1B). These findings suggested miR-503’s possible involvement in CFs proliferation. Apelin-13 protein expression was decreased in both TAC cardiac ventricles and CFs treated with Ang II and serum (Fig. 1C and D).

**miR-503 promoted the proliferation of CFs**

The effects of miR-503 on neonatal CFs proliferation were evaluated via an MTT assay. Overexpression of miR-503 (50 nmol/l) resulted in increased CFs proliferation ($n = 32, P < 0.05$), whereas cotransfection with AMO-503 (100 nmol/l), a specific inhibitor of miR-503, abrogated its effects (Fig. 2A).
Similarly, the overexpression of miR-503 elevated the mRNA levels of collagen I and collagen III, while up-regulated the expressions of CTGF and TGF-β. Cotransfection with AMO-503 suppressed collagen I, collagen III, CTGF and TGF-β up-regulation (Fig. 2B–G).

**Inhibition of antagomiR-503 on TAC-induced cardiac fibrosis**

To support the role of miR-503 in heart fibrosis development, an *in vivo* experiment is performed to investigate whether administration of antagomiR-503 (miR-503 inhibitor) could decrease TAC-induced cardiac fibrosis. After TAC surgery, we injected the antagomiR-503 30 mg/kg one time a day by tail vein on days 1, 2, 8, 9, 15 and 16. Twenty-eight days after surgery, we evaluate their cardiac function and measure the fibrotic factors using heart tissue. As Table 2 showed, EF and FS was elevated and LVDd and LVDs were decreased in the antagomiR-503 group, compared to TAC group. The results showed that the antagomiR-503 could improve the cardiac function induced by TAC. The Real-time PCR and Western Blot results showed that the antagomiR-503 inhibited the production of collagen I and III and down-regulated the expression of TGF and CTGF, compared to TAC group (As shown in the Fig. 3A–F).

**Table 2** Echocardiography of TAC mice after treatment with antagomiR-503 for 4 weeks

|                | Sham (*n = 6*) | TAC (*n = 6*) | TAC+antagomiR-503 (*n = 6*) | TAC+antagomiR-NC (*n = 6*) |
|----------------|---------------|---------------|------------------------------|----------------------------|
| LVDd, mm       | 3.14 ± 0.12   | 5.34 ± 0.19*  | 3.76 ± 0.19†                | 4.94 ± 0.23                |
| LVDs, mm       | 2.07 ± 0.12   | 3.26 ± 0.15*  | 2.68 ± 0.24†                | 3.06 ± 0.14                |
| IVSd, mm       | 0.72 ± 0.02   | 0.75 ± 0.04   | 0.83 ± 0.02                 | 0.68 ± 0.05                |
| IVSs, mm       | 0.85 ± 0.03   | 0.91 ± 0.03   | 0.91 ± 0.03                 | 0.89 ± 0.04                |
| FS, %          | 44.1 ± 1.5    | 21.1 ± 2.72*  | 32.9 ± 3.46†                | 29.1 ± 2.72                |
| EF, %          | 84.1 ± 3.7    | 42.9 ± 3.17*  | 66.1 ± 5.43†                | 54.6 ± 3.23                |

*P < 0.05 versus sham.
†P < 0.05 versus TAC.

Data are expressed as mean ± S.E.M.

LVDd: left ventricular diastolic diameter; LVDs: left ventricular systolic diameter; IVSd: interventricular septum diastolic thickness; IVSs: interventricular septum systolic thickness; FS: fractional shortening; EF: ejection fraction.
The 3′UTR of Apelin-13 mRNA was the target of miR-503

Our computational analysis predicted that miR-503 has the potential to suppress Apelin-13: the 3′-untranslated region of Apelin-13 mRNA contains one binding site for miR-503 among humans, rats and mice (Fig. 4A). In this study, we confirmed the regulation of Apelin-13 by miR-503 using a luciferase assay. We found that miR-503 (50 nmol/l) significantly inhibited the activity of luciferase vectors containing the 3′-untranslated region of Apelin-13 mRNA, which was rescued by co-application of AMO-503 (100 nmol/l). The specificity action of miR-503 was determined by the absence of changes, an absence that coincided with the use of NC-a negative control (Fig. 4B).

The 3′UTR of Apelin-13 mRNA was a direct target of miR-503. We then determined if the expression of Apelin-13 was affected by the overexpression of miR-503. Our data indicated that mRNA levels were changed by transfected miR-503 (Fig. 3C), whereas the protein levels of Apelin-13 were decreased (Fig. 3D).

To further confirm the role played by Apelin-13 in the proliferative actions of miR-503, we pre-treated CFs with 100 nmol/l Apelin-13 prior to the transfection of miR-503 and examined any subsequent CFs proliferation. Transfection with miR-503 (50 nmol/l) increased the production of collagen I and III and up-regulated the protein and mRNA expression levels of TGF-β and CTGF. Co-application of Apelin-13 100 nmol/l successfully suppressed collagen I and III, TGF-β and CTGF (Fig. 5A–F). These data suggest that Apelin-13 plays an important role in miR-503-mediated fibrosis.

Involvement of Apelin-13 in miR-503-mediated promotion of CFs proliferation

To further prove miR-503/APLN/TGF-β-CTGF pathway, we transfected AMO-503 into CFs treated with siRNA-APLN (APLN blocker) and detected the expression of TGF-β and CTGF. In the CFs with pre-treatment of Ang II (100 nmol/l), we transfected AMO-503 (100 nmol/l) into the cells treated with siRNA-APLN (50 nmol/l) and siRNA-NC (50 nmol/l) respectively. AMO-503 inhibited the production of collagen I and III and the expression of TGF-β and CTGF induced by Ang II. Cotransfection with siRNA-APLN abolished the effects of AMO-503 on the production of collagen I and III and the expression of TGF-β.
and CTGF. Cotransfection with siRNA-NC did not affect the production of collagen I and III and the expression of TGF-β and CTGF in the CFs with treatment of AMO-503 (Fig. 6A-F). These studies in vitro proved the role of miR-503 in heart fibrosis development by APLN/TGF-β and CTGF pathway.

**Apelin-13 inhibits angiotensin II-induced fibrotic responses via a TGF-CTGF dependent mechanism**

Ang II promotes cardiac fibrosis, which induces collagen accumulation and contributes to cardiac remodelling. The effects of Apelin-13 on neonatal CFs proliferation were evaluated via an MTT assay. Apelin-13 (1, 10 and 100 nmol/l) significantly decreased CFs proliferation induced by Ang II \((n = 34, P < 0.05)\) in a dose-dependent manner (Fig. 7A). Apelin-13 (1, 10, and 100 nmol/l) decreased the production of collagen I and III induced by Ang II (Fig. 7B and C).

In addition to blocking collagen, Apelin-13 (1, 10, and 100 nmol/l) inhibited the angiotensin II-induced elevation of TGF-β and CTGF at both the mRNA and protein levels, in a dose-dependent manner (Fig. 7D-G).

**Discussion**

In this study, we found that miR-503 was up-regulated in mouse hearts subjected to TAC and that miR-503 could induce the proliferation of CFs and enhance the ECM deposition, which resulted in cardiac fibrosis. Moreover, our data also strongly suggested that miR-503 functioned as a direct epigenetic regulator of Apelin-13.

miRNA expression has tissue specificity that determines the specific types of miRNA contributes to the biological and pathological processes of a particular organ [7]. miRNA dysregulation is a common phenomenon that occurs in various diseases. miR-503 was up-regulated in endothelial cell from diabetic GK rats and contributes to diabetes mellitus-induced impairment of endothelial functions and reparative angiogenesis following limb ischemia [22]. ECs dysfunction and, for example, endothelial to mesenchymal transition, may contribute to cardiac fibrosis. miR-503 may be influenced by the behaviour of ECs and be involved in cardiac fibrosis. miR-503 was down-regulated in PAH, targeting in FGF2 and exerted antiproliferative effects in PAECs [23]. Recent studies have proposed that miR-503 is a growth suppressor in many cancer cells and overexpression of miR-503 significantly inhibited cell proliferation, migration and invasion [24–27]. On the contrary, we found miR-503 promoted myocardial fibroblasts proliferation. This result may be because of the myocardial cells belong to terminal-differentiated cells. So the regulating mechanisms of miR-503 were different in the two kinds of cells.

In this study, we observed that the expression of miR-503 was up-regulated in TAC mice, as well as in proliferating CFs treated with serum or AngII. These results suggested that CFs were regulated by miR-503. This idea was verified by the finding that the overexpression of miR-503 promoted cardiac fibrosis, increased CFs collagen production.

To confirm miR-503 function on cardiac fibrosis, we injected antagoniR-503 in the TAC mice and evaluated their cardiac function and measure the fibrotic factors using heart tissue. Echocardiographic results showed that the antagoniR-503 could improve the cardiac function induced by TAC. The real-time PCR and Western Blot results showed that the antagoniR-503 inhibited the production of collagen I and III and down-regulated the
expression of TGF and CTGF. These data in vivo showed that the administration of antagomiR-503 could inhibit TAC-induced cardiac fibrosis and supported the role of miR-503 in heart fibrosis development. miR-503 is a promising therapeutic target for reducing cardiac fibrosis.

Several miRNAs has been linked to regulate the development and progression of cardiac fibrosis via regulation of various proteins associated with fibrosis. miR-21 levels were increased and augmented ERK-MAP kinase activity through the inhibition of sprouty homologue 1 (Spry1) in fibroblasts of the failing heart [27]. miR-133 and miR-30 directly down-regulated connective tissue growth factor, a powerful inducer of ECM synthesis and regulated interstitial fibrosis. Apelin-13 is the endogenous peptide ligand of the Apelin-13 receptor (APJ) and has emerged as a novel endogenous counter-regulatory mechanism of Ang II. Apelin-13 elicits compensatory vasorelaxation under pathological conditions, including vascular endothelial dysfunction [28]. Apelin-13 protects against Ang II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production [29]. In this study, we explored the regulatory effects of Apelin-13 on collagen expression and its role in mediating the fibrotic actions of miR-503. It is well-known that Ang II is an inducer of TGF-β expression, so we used the neonatal CFs with pre-treatment of Ang II and then observed that the effect of Apelin-13 on the production of collagen proteins and the expression of TGF-β and CTGF. Pre-treatment with Apelin-13 inhibited the activation of CTGF and TGF-β induced by the cotransfection of miR-503.

To further prove the effects of miR-503 on cardiac fibrosis by targeting APLN, in the CFs with pre-treatment of AngII, we transfected AMO-503 into the cells treated with siRNA-APLN. AMO-503 inhibited the production of collagen I and III and the expression of TGF-β-CTGF induced by Ang II. Cotransfection of AMO-503 with siRNA-APLN abolished the effects of AMO-503 on the production of collagen I and III and the expression of TGF-β-CTGF. Cotransfection with siRNA-NC did not affect the production of collagen I and III and the expression of TGF-β and CTGF in the CFs with AMO-503. These studies in vitro proved the role of miR-503 in heart fibrosis development by APLN/ TGF-β-CTGF pathway.

Additionally, in silico predictions with Targetscan demonstrated that Apelin-13 is a target of miR-503, a phenomenon that is conserved among species. Our results confirmed the regulation of Apelin-13 by miR-503 using both a luciferase reporting method and a protein expression technique. One miRNA regulates hundreds of mRNAs. Other targets of miR-503 have been confirmed previously, including enhancers of mitogen-activated protein kinase fibroblast growth factor 2 (basic), cyclin D2 and cyclin E1. Although our data strongly support the involvement of Apelin-13 in miR-503-mediated fibrotic effects, we cannot rule out the participation of other genes in this process. The miR-503 sequence is identical among various species, including humans and rats, implying that the effects of miR-503 on cardiac fibrosis observed in this study may be extrapolated to human beings. Our study determined that miR-503 modulated the expression of Apelin-13 in the setting of fibrosis. It was reported that in pulmonary artery endothelial cells, down-regulation miR-503 by Apelin-13 increased expression of FGF2 to promote endothelial cell proliferation [23]. This result hinted there may be a regulating mechanism between miRNAs and protein signalling pathways. Future studies will be needed to evaluate the hypothesis.

Transforming growth factor-β and its downstream effector, CTGF/CCN2, are fibrogenic activators. The TGF-β-CTGF pathway activates cells with a fibrogenetic phenotype and initiated cellular processes underlying fibrosis [30, 31]. Connective tissue growth factor has also been involved in the induction of cardiac fibrosis in animal models of LV remodelling [32, 33]. In our study, we observed that overexpression of miR-503 increased the expression of TGF-β and CTGF in CFs, an effect that was abolished by the co-application of Apelin-13.

In conclusion, miR-503 decreased Apelin-13 activity by targeting the promoter region of the Apelin-13 gene by binding to its 3'-UTR and up-regulating the TGF-β-CTGF pathway. Down-regulation
Fig. 6 siRNA-APLN abolished the effects of AMO-503 in the CFs with pre-treatment of Ang II (100 nmol/l). We transfected AMO-503 (100 nmol/l) into the cells treated with siRNA-APLN (50 nmol/l) and siRNA-NC (50 nmol/l). (A and B) AMO-503 inhibited the production of collagen I and III induced by Ang II in CFs. (C-F) Effects of antagoniR-503 on the protein and mRNA levels of transforming growth factor-β (TGF-β) (C and D) and its downstream molecule, CTGF (E and F). Data are expressed as the means ± S.E.M.; n = 5-6. NC indicates negative control. *P < 0.05 versus control (Ctl); #P < 0.05 versus Ang II, $P < 0.05 versus Ang II AMO503.

Fig. 7 Apelin-13 inhibits angiotensin II-induced fibrotic responses via TGF-β-CTGF-dependent mechanisms. (A) The MTT test demonstrated that Apelin-13 (1, 10, and 100 nmol/l) inhibited the proliferation of CFs treated with Ang II (100 nmol/l) in a dose-dependent manner. (B and C) Apelin-13 decreased the expression levels of collagen I and collagen III in CFs treated with Ang II. (D and E) The effects of Apelin-13 on the protein and mRNA levels of TGF-β in CFs treated with Ang II. (F and G) The effects of Apelin-13 on the protein and mRNA levels of CTGF in CFs treated with Ang II. Data are expressed as the means ± S.E.M.; n = 6. *P < 0.05 versus control (no treatment); #P < 0.05 versus Ang II.
of Apelin-13 by miR-503 induced production of collagen and induced cardiac fibrosis. The findings of this study highlight important clinical implications relative to miR-503 in the setting of cardiac fibrosis.

Acknowledgements

This project was supported by the National Basic Research Program of China (973 Program 2013 CB331104), the Outstanding Youth Science Fund Project of Heilongjiang Province (JC201411) and the National Natural Science Foundation of China (81400294 and 81573437).

References

1. Brown RD, Ambler SK, Mitchell MD, et al. Cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol. 2005; 45: 657–87.
2. Jugdutt BI. Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets Cardiovasc Haematol Disord. 2003; 3: 1–30.
3. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther. 2009; 123: 255–78.
4. Yang B, Lin H, Xiao J, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med. 2007; 13: 486–91.
5. Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007; 13: 613–8.
6. Sayed D, Hong C, Chen Y, et al. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res. 2007; 100: 416–24.
7. van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA. 2006; 103: 8255–60.
8. Ren XP, Wu J, Wang X, et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation. 2009; 119: 2357–66.
9. Abonnenc M, Nabeelbacac A, Mayr U, et al. Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29a and microRNA-30c. Circ Res. 2013; 113: 1138–47.
10. Dai Y, Dai D, Mehta JL. MicroRNA-29a, a mysterious regulator in myocardial fibrosis and circulating miR-29a as a biomarker. J Am Coll Cardiol. 2014; 64: 2181.
11. Roy S, Khanna S, Hussain SR, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloproteinase-2 via phosphatase and tensin homologue. Cardiovasc Res. 2009; 82: 21–9.
12. Pan Z, Sun X, Shan H, et al. MicroRNA-101 inhibited postischemic cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-β1 pathway. Circulation. 2012; 126: 840–50.
13. Dai Y, Khabdakov M, Wang X, et al. MicroRNAs involved in the regulation of posts ischemic cardiac fibrosis. Hypertension. 2013; 61: 751–6.
14. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998; 251: 471–6.
15. Pechjetski D, Foussal C, Alfarano C, et al. Apelin-13 prevents cardiac fibroblast activation and collagen production through inhibition of sphenocine kinase 1. Eur Heart J. 2012; 33: 2360–9.
16. Li L, Zeng H, Chen JX. Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction. Am J Physiol Heart Circ Physiol. 2012; 303: H605–18.
17. Zhao JJ, Yang J, Lin J. Identification of microRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst. 2009; 25: 13–20.
18. Caporali A, Emanuelli C. MicroRNA-503 and the extended microRNA-16 family in angiogenesis. Trends Cardiovasc Med. 2011; 21: 162–6.
19. Corbeta S, Vaira V, Guarnieri V. Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer. 2010; 17: 135–46.
20. Tombol Z, Szabó PM, Molnár V. Integrative molecular bioinformatics study of human adrenocortical tumors: MicroRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer. 2009; 16: 895–906.
21. Wang XH, Qian RZ, Zhang W. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol. 2009; 36: 181–8.
22. Caporali A, Meloni M, Völlkenke C, et al. Derepression of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and repressive angio genesis after limb ischemia. Circulation. 2011; 123: 282–91.
23. Kim J, Kang Y, Kojima Y, et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med. 2013; 19: 74–82.
24. Peng Y, Liu YM, Li LC, et al. microRNA-503 inhibits gastric cancer cell growth and epithelial-to-mesenchymal transition. Oncol Lett. 2014; 7: 1233–8.
25. Zhang Y, Chen X, Lian H, et al. MicroRNA-503 acts as a tumor suppressor in glioblastoma for multiple antitumor effects by targeting IGF-1R. Oncol Rep. 2014; 31: 1445–52.
26. Xiao F, Zhang W, Chen L, et al. MicroRNA-503 inhibits the G1/S transition by downregulating cyclin D3 and E2F3 in hepatocellular carcinoma. J Transl Med. 2013; 11: 195.
27. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease...
by stimulating MAP kinase signalling in fibroblasts. *Nature*. 2008; 456: 980–4.

28. Nagano K, Ishida J, Unno M, et al. Apelin elevates blood pressure in ICR mice with L-NAME-induced endothelial dysfunction. *Mol Med Rep*. 2013; 7: 1371–5.

29. Siddiquee K, Hampton J, Khan S, et al. Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. *J Hypertens*. 2011; 29: 724–31.

30. Haydont V, Mathé D, Bourgier C, et al. Induction of CTGF by TGF-beta1 in normal and radiation enteritis human smooth muscle cells: Smad/Rho balance and therapeutic perspectives. *Radiother Oncol*. 2005; 76: 219–25.

31. Tzortzaki EG, Antoniou KM, Zervou MI, et al. Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis. *Respir Med*. 2007; 101: 821–9.

32. Frazier K, Williams S, Kothapalli D, et al. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. *J Invest Dermatol*. 1996; 107: 404–11.

33. Shi-Wen X, Leask A, Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. *Cytokine Growth Factor Rev*. 2008; 19: 133–44.